Notably, the anti-CD44v6 peptide was more effective in tumor growth inhibition than inhibitors of CD44v6 interactions with coreceptors c-Met and vascular endothelial growth factor receptor 2 (VEGFR-2) (Matzke-Ogi et al., 2016). Here, MET is linked to neoplasm.